Following an abbreviated submission, the Scottish Medicines Consortium (SMC) has accepted methotrexate injection 50mg/ml (Metoject®) for use in NHS Scotland for the treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy (phototherapy, PUVA, and retinoids), and severe psoriatic arthritis in adult patients.

The drug advice notes that this is the first licensed parenteral formulation of methotrexate.  Please see the link below for further details.